ORS Puts Focus on Atypical Fractures

Translational Research Symposium offers three perspectives

Amber Blake

For people with osteoporosis, the use of bisphosphonates has been helpful in reducing the risk of bone fractures. However, recent studies suggest that the long-term use of bisphosphonates might actually play a contributing role in atypical fractures of the femur or long bone of the thigh. These concerns have led the U.S. Food and Drug Administration (FDA) to recommend updates to bisphosphonate labeling.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!

Advertisements


Advertisement